Shares in Tandem Diabetes Care (NSDQ:TNDM) rose yesterday after the insulin pump maker beat expectations on Wall Street with its fourth quarter and full-year results.
The San Diego Calif.-based company reeled in its losses in Q4, posting a net loss of -$11.4 million on sales of $40.3 million for the 3 months ended Dec. 31, for sales growth of 39% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Tandem Diabetes sales up 40% in Q4 appeared first on MassDevice.